Veracyte, Inc.
VCYT
$43.34
-4.22%
Veracyte, Inc. is a genomic diagnostics company that provides tests for prostate, thyroid, breast, and bladder cancers, empowering clinicians with insights for cancer diagnosis and treatment decisions. The company holds a distinct position in the precision medicine space, leveraging its proprietary genomic platforms to offer differentiated tests such as Decipher and Afirma. Currently, the stock is under scrutiny due to a recent sharp pullback after a strong run-up, with investors debating whether the decline represents a buying opportunity or a correction in an overextended growth story. The company's focus on expanding its test menu and international reach remains central to its growth narrative.…
VCYT
Veracyte, Inc.
$43.34
Related headlines
VCYT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veracyte, Inc.'s 12-month outlook, with a consensus price target around $57.82 and implied upside of +33.4% versus the current price.
Average Target
$57.82
0 analysts
Implied Upside
+33.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $70
Analyst target range
Veracyte is covered by 11 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.67 (where 1 is Strong Buy and 5 is Sell). The average target price is $57.82, implying an upside of approximately 33% from the current price of $43.34. The target range spans from $44.00 (low) to $70.00 (high), with the high target suggesting strong growth expectations, while the low target reflects potential downside risks. The wide spread between low and high targets indicates high uncertainty, but the overall bullish consensus suggests analysts see the recent pullback as a buying opportunity.
VCYT Technical Analysis
Veracyte's stock has exhibited a strong uptrend over the past year, with a 1-year price change of +44.7%, significantly outperforming the S&P 500's +18.6% gain. The current price of $43.34 sits at approximately 71% of the 52-week range (low $29.375, high $60.91), indicating that the stock has pulled back from its highs but remains well above its lows. This positioning suggests a consolidation phase after a substantial rally, with the stock still in a longer-term bullish structure.
Beta
1.94
1.94x market volatility
Max Drawdown
-39.2%
Largest decline past year
52-Week Range
$29-$61
Price range past year
Annual Return
+44.7%
Cumulative gain past year
| Period | VCYT Return | S&P 500 |
|---|---|---|
| 1m | -22.2% | +3.0% |
| 3m | -6.5% | +1.4% |
| 6m | +18.4% | +13.1% |
| 1y | +44.7% | +19.3% |
| ytd | +2.2% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VCYT Fundamental Analysis
Veracyte's revenue growth has been robust, with the most recent quarterly revenue estimated at $945.7 million (annualized), reflecting a strong trajectory. The company's gross margin stands at 69.6%, indicating a high-margin business model typical of diagnostics. Net income is positive, with an EPS of $0.02, and the net margin is 12.8%, showing profitability. Operating margin is 14.3%, suggesting efficient cost management. The company's balance sheet is solid, with a current ratio of 8.15 and a very low debt-to-equity ratio of 0.03, indicating minimal leverage. ROE is 5.07%, which is modest but positive, and the company generates sufficient cash flow to fund operations, as evidenced by a positive PCF ratio of 24.27.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VCYT Overvalued?
Given that Veracyte is profitable, the PE ratio is the primary valuation metric. The trailing PE is 50.1x, while the forward PE is 22.2x, implying the market expects significant earnings growth. The PEG ratio of 0.31 suggests the stock is undervalued relative to its growth rate. Compared to the industry average, Veracyte's PS ratio of 6.4x is higher than the sector median, but this premium is justified by its superior growth and margins. Historically, the stock's valuation is within its normal range, with the current PE below its historical peak, indicating that the market is pricing in optimistic but not extreme expectations.
PE
50.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple